PMID- 36331673
OWN - NLM
STAT- MEDLINE
DCOM- 20230323
LR  - 20230512
IS  - 1573-0646 (Electronic)
IS  - 0167-6997 (Linking)
VI  - 41
IP  - 1
DP  - 2023 Feb
TI  - Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous 
      cell carcinoma.
PG  - 168-172
LID - 10.1007/s10637-022-01312-9 [doi]
AB  - BACKGROUND: The efficacy and safety of the anti-EGFR antibody necitumumab 
      combined with gemcitabine and cisplatin (N + GC) in the first-line treatment of 
      advanced lung squamous cell carcinoma (LSCC) have been proven. However, the 
      efficacy and safety of N + GC in the second line or later treatment remain 
      unclear. METHODS: Eleven patients who received N + GC for advanced-stage or 
      recurrent LSCC were enrolled. We retrospectively assessed the patients' clinical 
      characteristics and efficacy and safety of treatment. RESULTS: The median patient 
      age was 73 years (range, 63-77 years). The cohort included nine (81.8%) men and 
      two (18.2%) women. Two (18.2%) patients had postoperative recurrence, and one 
      (9.1%), three (27.3%), one (9.1%), and four (36.4%) patients were diagnosed with 
      stage IIIA, IIIB, IVA, and IVB disease, respectively. Concerning the best overall 
      response, partial response was achieved in five (45.5%) patients, four (36.4%) 
      patients displayed stable disease, and two (18.2%) patients were not evaluable. 
      Median progression-free survival was 6.8 months (range, 1.4-10.3 months). The 
      grade 3 or higher neutropenia, thrombocytopenia, and anemia occurred in six 
      (54.5%), three (27.3%), and two (18.2%) patients, respectively. Additionally, 
      grade 3 skin reaction, rash, lung infection, duodenal ulcer, and febrile 
      neutropenia were observed in one (9.1%) patient each. Two (18.2%) patients 
      required treatment interruption because of adverse events. CONCLUSION: N + GC 
      displayed good efficacy in the second line or later treatment among patients with 
      LSCC. This study suggested that N + GC is a useful option even after second-line 
      treatment of advanced-stage or recurrent LSCC, although the management of adverse 
      events is essential.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Kinoshita, Fumihiko
AU  - Kinoshita F
AD  - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer 
      Center, 3-1-1 Notame, Minami-ku, 811-1395, Fukuoka, Japan. 
      kinoshita2315@gmail.com.
FAU - Oku, Yuka
AU  - Oku Y
AD  - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer 
      Center, 3-1-1 Notame, Minami-ku, 811-1395, Fukuoka, Japan.
FAU - Takamori, Shinkichi
AU  - Takamori S
AD  - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer 
      Center, 3-1-1 Notame, Minami-ku, 811-1395, Fukuoka, Japan.
FAU - Fujishita, Takatoshi
AU  - Fujishita T
AD  - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer 
      Center, 3-1-1 Notame, Minami-ku, 811-1395, Fukuoka, Japan.
FAU - Toyozawa, Ryo
AU  - Toyozawa R
AD  - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer 
      Center, 3-1-1 Notame, Minami-ku, 811-1395, Fukuoka, Japan.
FAU - Ito, Kensaku
AU  - Ito K
AD  - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer 
      Center, 3-1-1 Notame, Minami-ku, 811-1395, Fukuoka, Japan.
FAU - Shoji, Fumihiro
AU  - Shoji F
AD  - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer 
      Center, 3-1-1 Notame, Minami-ku, 811-1395, Fukuoka, Japan.
FAU - Okamoto, Tatsuro
AU  - Okamoto T
AD  - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer 
      Center, 3-1-1 Notame, Minami-ku, 811-1395, Fukuoka, Japan.
LA  - eng
PT  - Journal Article
DEP - 20221104
PL  - United States
TA  - Invest New Drugs
JT  - Investigational new drugs
JID - 8309330
RN  - 0 (Gemcitabine)
RN  - Q20Q21Q62J (Cisplatin)
RN  - 2BT4C47RUI (necitumumab)
RN  - 0 (Antibodies, Monoclonal)
SB  - IM
MH  - Male
MH  - Humans
MH  - Female
MH  - Middle Aged
MH  - Aged
MH  - Gemcitabine
MH  - Cisplatin/adverse effects
MH  - *Lung Neoplasms/pathology
MH  - Retrospective Studies
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Treatment Outcome
MH  - Neoplasm Staging
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - *Carcinoma, Squamous Cell/pathology
MH  - Lung/pathology
OTO - NOTNLM
OT  - Chemotherapy
OT  - Lung cancer
OT  - Necitumumab
OT  - Squamous cell carcinoma
EDAT- 2022/11/05 06:00
MHDA- 2023/03/24 06:00
CRDT- 2022/11/04 12:18
PHST- 2022/09/23 00:00 [received]
PHST- 2022/10/07 00:00 [accepted]
PHST- 2022/11/05 06:00 [pubmed]
PHST- 2023/03/24 06:00 [medline]
PHST- 2022/11/04 12:18 [entrez]
AID - 10.1007/s10637-022-01312-9 [pii]
AID - 10.1007/s10637-022-01312-9 [doi]
PST - ppublish
SO  - Invest New Drugs. 2023 Feb;41(1):168-172. doi: 10.1007/s10637-022-01312-9. Epub 
      2022 Nov 4.